|
| Status |
Public on Jun 14, 2021 |
| Title |
Secondary Resistance to Anti-EGFR Therapy by Transcriptional Reprogramming in Patient-Derived Colorectal Cancer Models |
| Organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
3' RNA-seq of patient derived colon cancer xenograft models (N=10) showing initial disease control under cetuximab treatment were collected. All xenograft models were wildtype for KRAS, NRAS, BRAF and PIK3CA. All mice were treated with cetuximab (Merck Serono) by intra peritoneal (i.p.) injection twice per week and dosed at 25mg/kg to establish response characteristics. Tumors were chronically treated to establish cetuximab secondary resistant tumors .
|
| |
|
| Overall design |
Three conditions were generated for comparisons: untreated control (K), 5 days cetuximab treatment (5dC) while pdx tumors were responsive to cetuximab and cetuximab secondary resistant tumors (C) following chronic cetuximab treatment.
|
| |
|
| Contributor(s) |
Hahn SA, Admard J |
| Citation(s) |
34271981 |
| |
| Submission date |
Dec 11, 2019 |
| Last update date |
Jul 27, 2021 |
| Contact name |
Jakob Admard |
| Organization name |
Universitätsklinikum Tübingen
|
| Department |
Institut für Medizinische Genetik und Angewandte Genomik
|
| Street address |
Calwerstr. 7
|
| City |
Tübingen |
| ZIP/Postal code |
72076 |
| Country |
Germany |
| |
|
| Platforms (2) |
| GPL19415 |
Illumina NextSeq 500 (Homo sapiens; Mus musculus) |
| GPL25526 |
Illumina NovaSeq 6000 (Homo sapiens; Mus musculus) |
|
| Samples (50)
|
|
| Relations |
| BioProject |
PRJNA594974 |
| SRA |
SRP236891 |
Less...
More...